Answer
Trastuzumab emtansine has an elimination half-life of approximately 4 days following intravenous administration in patients with HER2-positive metastatic breast cancer, based on population pharmacokinetic analysis.
Sources for this answer
- Kadcyla 100 mg and 160 mg Powder for Concentrate for Solution for InfusionRoche Products Limited · emc · SmPC §5.2 Pharmacokinetic properties · Version 20Document updated
Sources checked